Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
  • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
  • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
  • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
  • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K38/00—Medicinal preparations containing peptides
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K2317/00—Immunoglobulins specific features
  • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
  • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K2317/00—Immunoglobulins specific features
  • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
  • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
  • C07K2317/565—Complementarity determining region [CDR]
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N2740/00—Reverse transcribing RNA viruses
  • C12N2740/00011—Details
  • C12N2740/10011—Retroviridae
  • C12N2740/16011—Human Immunodeficiency Virus, HIV
  • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
  • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
• • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
  • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
  • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
  • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
  • Y10S530/867—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving immunoglobulin or antibody produced via recombinant dna technology

Definitions

• the invention relates to new humanized monoclonal antibodies
• the invention relates, furthermore, to humanized and chimeric
• the invention discloses the amino acid sequences of the responding antigen-binding site for this receptor.
• the invention relates to pharmaceutical compositions compris ⁇ ing the said antibodies for the purposes of treating tumors like melanoma, glioma or carcinoma.
• the said antibodies can be used also for diagnostic applications regarding locating and assessing the said tumors in vitro or in vivo.
• Humanized antibodies mean antibodies comprising FRs of the variable regions and constant regions of amino acids located in the light and heavy chain which derive from human sources whereas the hypervariable regions derive from non-human sources.
• Chimeric antibodies mean antibodies comprising variable and hypervariable regions which derive from non-human sources whereas the constant regions derive from human origin.
• FRs mean the framework regions of an antibody and are found within the variable regions. In these regions a certain alteration of amino acids occurs.
• CDRs mean the complementarity determining or "hypervari ⁇ able” regions of an antibody and are found within the vari ⁇ able regions. These regions represent the specific antigen- binding site and show an immense exchange of amino acids. CDRs are primarily responsible for the binding affinity of the antigen.
• Consensus sequence means a non-naturally occurring amino acid sequence as light or heavy chain variable regions and is used as substitute for the originally present non-human heavy or light chain variable regions.
• the consensus sequences is synthetic and therefore an artificial sequence of the most common amino acids of a distinct class or subclass or sub ⁇ group of heavy or light chains of human immunoglobluins.
• EGF and EGFR mean the Epidermal Growth Factor and its receptor.
• V L regions mean light chain variable regions.
• V H regions mean heavy chain variable regions.
• the murine monoclonal antibody 425 (MAb 425) was raised against the human A431 carcinoma cell line and found to bind to a polypeptide epitope on the external domain of the human
• epidermal growth factor receptor EGFR
• EGF epidermal growth factor
• Enhanced expression of EGFR is found to occur on malignant tissue from a variety of sources thus making MAb 425 a possi-
• MAb 425 was found to mediate tumor cytotoxicity in vitro and to suppress tumor cell growth of epidermoid and colorectal carcinoma-derived cell lines in vitro (Rodeck et al., 1987) . Radiolabelled MAb 425 has also
• mice 20 been shown to bind to xenografts of human malignant gliomas in mice (Takahashi et al., 1987) .
• EGF is a polypeptide hormone which is mitogenic for epidermal and epithelial cells. When EGF interacts with sensitive 5 cells, it binds to membrane receptors; the receptor EGF complexes cluster and then are internalized in endocytotic vesicles. This is responsible for the phenomenon of "down- regulation" . EGF binding induces a tyrosine kinase activity of the receptor molecule and induces synthesis of DNA. 0
• the EGF-receptor is a transmembrane glycoprotein of about 170,000 Daltons (Cohen, 1982) . It is the gene product of the c-erb-B proto-oncogene (Downward et al.. Nature. Vol. 307, pp. 521-527, 1984) .
• the receptor exists in two kinetic forms: so-called low affinity and high-affinity receptors.
• the A431 carcinoma cell line expresses abundant EGF-receptors on its cell surfaces, and thus has been used in many studies to generate anti-EGF-receptor antibodies.
• the recep- tors on A431 differ from those of other cell types in the carbohydrate moieties attached to the polypeptide.
• many antibodies raised against A431 membranes are directed against carbohydrates which are not common to all forms of the recep ⁇ tor molecule (e.g. Schreiber, 1983) .
• EGF-receptors Other monoclonal antibodies are reactive with the protein moiety of EGF-receptors. These antibodies display a variety of properties upon binding to EGF-receptors, presumably dependent on the particular portion of the receptor molecule bound, and the isotype of the antibody. Some antibodies mimic some of the effects of EGF (agonists) and some inhibit the effects (antagonists) .
• EGF-receptors have been implicated in the pro- gression of tumor growth.
• the gene for the receptors has been found to be the cellular analogue of the avian viral oncogene v-erb-B ( ⁇ lrich, 1984) .
• an association has been detected between late stages of melanoma development and extra copies of the chromosome carrying the receptor gene (Koprowski et al.. Somatic Cell and Molecular Genetics, Vol. 11, pp. 297-302, 1985) .
• EGF-receptors Because of EGF-receptors are expressed on a wide variety of solid tumors they provide a suitable target for anti-tumor therapy. However, there is a need in the art for a suitable anti-receptor antibody.
• antibodies which mimic the effects of EGF could stimulate the progression of the tumor rather than arresting it.
• Other antibodies which only bind to high or low affinity receptors could be less than optimally effective because EGF could still exert its effect through the unbound receptors.
• Still other antibodies convert low affinity recep ⁇ tors to high affinity receptors, which could exacerbate tumor growth rather than inhibiting it.
• murine MAbs have been used for therapeutic treatment in humans, they have elicited an immune response (Giorgi et al., 1983/ Jaffers et al., 1986) .
• several groups have tried to "humanize” murine antibodies. This can involve one of two approaches. Firstly, the murine constant region domains for both the light and heavy chain can be replaced with human constant regions. Such "chimeric" murine-human antibodies have been successfully constructed from several murine antibodies directed against human tumor- associated antigens (Sun et al., 1987/ Whittle et al., 1987 / Liu et al., 1987/ Gillies and Wesolowski, 1990) .
• EP 088 994 proposes the construction of recombinant DNA vectors comprising of a DNA sequence which codes for a vari ⁇ able domain of a light or a heavy chain of an immunoglobulin specific for a predetermined ligand.
• the application does not contemplate variations in the sequence of the variable domain.
• EP 102 634 describes the cloning and expression in bacterial host organisms of genes coding for the whole or a part of human IgG heavy chain polypeptide, but does not contemplate variations in the sequence of the polypeptide.
• EP 239 400 proposes that humanized antibodies can be obtained by replacing the antigen-binding site (hypervariable regions) of any human antibody by an antigen-binding site of a non-hu ⁇ man, for example of a mouse or a rat antibody by genetechno- logical methods.
• human or humanized antibodies can be manufactured having specific antigen-binding sites which were not available up to now in antibodies originating from humans.
• Chimeric antibodies can be obtained by replacing not only the CDRs but the whole variable regions of the light and heavy chains. Chimeric antibodies, however, can still be immuno- genie. Chimeric antibodies are, however, very useful for diagnostic purposes and optimizing humanized antibodies.
• the affinity of the antigen-binding sites can be influenced by selective exchange of some single amino acids within the variable regions which are not directly part of the CDRs (Reichmann et al., 1988) .
• the invention has the object of providing a humanized monoclonal antibody which is, in particular, directed to the EGF-receptor, comprising an antigen-binding site of non-human sources and the FRs of the variable regions and constant regions of human origins, which are, if necessary, modified in a way that the specificity of the binding site can be conserved or restored.
• the invention has the object of characterizing the hypervariable regions of the antigen-binding site of an antibody against the EGF-receptor and providing these CDRs within a humanized monoclonal antibody defined as above.
• This antibody and its chimeric variant can play an important role as a therapeutic or diagnostic agent in order to combat tumors, as melanoma, glioma or carcinoma.
• the modifica ⁇ tions which are necessary according to the invention can be indicated with 0 to 10 %, or preferably, 1 to 5 % related to the exchange of amino acids.
• a humanized monoclonal antibody according to the invention has the following advantage: a consensus sequence which is a sequence according to the most common occurrence of amino acid on a distinct position of a chain of human immunoglobu- l of a defined class or subclass or subgroup, can be syn ⁇ thesized as a whole or as a part without problems. There is no dependence on the detailed knowledge or availability of certain individual antibodies or antibody fragments. That means that a wide range of individually and naturally occur- ring antibody fragments can be covered by providing a very restricted number of consensus sequences which are cloned into corresponding expression vectors.
• a consensus sequence may be favorable with respect to the immunogenicity in com ⁇ parison with individual natural sequences which are known to be sometimes epitopes for other antibodies (for example anti-idiotypic antibodies) .
• individual natural sequences which are known to be sometimes epitopes for other antibodies (for example anti-idiotypic antibodies) .
• a general principal teaching is disclosed according to the instant invention. It is not a mere accident with respect to the large number of possible sequences and combinations of sequences in the variable and hypervariable domains that the described teaching regarding the consensus sequence succeeded in constructing a humanized antibody directed to the EGF-re ⁇ ceptor.
• the heavy chains of the variable domains provide a greater contribution to the anti ⁇ gen-binding site than the corresponding light chains.
• the light chain of a humanized antibody having a consensus sequence it is not necessary to modify in the same manner the light chain of a humanized antibody having a consensus sequence. This is an interesting aspect because it is known that the light chains in some known natural antibodies play the more important role than the corresponding heavy chains (see Williams et al., 1990) .
• the invention provides for the first time the characterization, cloning and amplification by means of genetic engineering the antigen-binding site of a murine antibody against the EGF-receptor (MAb 425) .
• Corresponding oligonucleotides could be synthesized which code for that antigen-binding site and for the whole variable domain of a humanized and chimeric monoclonal antibody.
• the invention provides, moreover, correspondingly effective expression vectors which can be used for the transformation of suitable eukaryotic cells. -
• the invention relates to a humanized monoclonal anti ⁇ body comprising antigen bindings sites (CDRs) of non-human origin, and the FRs of variable regions and constant regions of light and heavy chains of human origin, characterized in that at least the FRs of the variable regions of the heavy chain comprise a modified consensus sequence of different variable regions of a distinct class or subgroup of a human immunoglobulin.
• CDRs antigen bindings sites
• the invention relates to a humanized mono ⁇ clonal antibody, wherein the FRs of the consensus sequence has a homology of at least 70 % compared with the amino acid sequence of the FRs of the variable region of the non-human antibody from which the antigen-binding sites originate.
• the invention relates to a humanized mono ⁇ clonal antibody, having the following properties:
• the invention relates to a humanized mono ⁇ clonal antibody, wherein the hypervariable regions of the antigen-binding sites comprise the following amino acid sequences: light chain
• the invention relates to a humanized mono- clonal antibody, wherein the FRs of the variable regions which are not related to the antigen-binding sites comprise the following amino acid sequence:
• the invention relates to a humanized mono ⁇ clonal antibody, wherein the constant regions of the heavy chain comprise the amino acid sequence of a gamma-1 chain, and the constant regions of the light chain comprise the amino acid sequence of a kappa chain of a human immunoglobu ⁇ lin.
• the invention relates to a humanized mono- clonal antibody, comprising a derivate of an amino acid sequence modified by amino acid deletion, substitution, addition or inversion within the variable and constant regions wherein the biological function of specific binding to the antigen is preserved.
• the invention relates to an expression vector, suitable for transformation of host cells, characterized in that it comprises a DNA sequence coding for the variable and/or constant regions of the light and/or heavy chains of a humanized antibody.
• the invention relates to humanized or chimeric monoclonal antibody, comprising hypervariable regions (CDRs) of antigen-binding sites of murine origin and the FRs of the variable regions of human or murine origin and constant regions of light and heavy chains of human origin, character ⁇ ized in that the hypervariable regions comprise the following amino acid sequences,
• the constant regions of the heavy chain comprise the amino acid sequence of a gamma-1 chain
• the constant regions of the light chain comprise the amino acid sequence of a kappa chain of a human immunoglobulin.
• the invention relates to a humanized mono ⁇ clonal antibody according to claim 12, wherein the FRs of the variable regions which are not related to the antigen-binding sites, are of human origin and comprise the following amino acid sequence,
• the invention relates to a chimeric monoclonal antibody according to Claim 12, wherein the FRs of the vari ⁇ able regions which are not related to the antigen-binding site, are of murine origin and comprise the following amino acid sequences:
• the invention relates to a process for the preparation of a humanized monoclonal antibody, comprising hypervariable regions (CDRs) of antigen-binding sites of non-human origin, and FRs of variable regions and constant regions of the light and heavy chains of human origin by cultivating transformed host cells in a culture medium and purification and isolation the expressed antibody proteins, characterized in
• the invention relates to a process, wherein DNA sequences are used coding for the following amino acid sequences which represent the hypervariable regions (CDRs) : light chain
• the invention relates to a process, wherein DNA sequences are used coding for the following amino acid sequences which represent the FRs of the variable regions :
• the invention relates to a process for the prepara- tion of a chimeric monoclonal antibody having the biological function of binding to epitopes of the EGF-receptor, compris ⁇ ing hypervariable regions (CDRs) of antigen-binding sites and FRs of variable regions of murine origin and FRs of variable regions of murine origin and constant regions of the light and heavy chains of human origin by cultivating trans ⁇ formed host cells in a culture medium and purification and isolation the expressed antibody proteins, characterized in that the host cells are transformed with expression vectors according to one of the expression vectors.
• CDRs hypervariable regions
• the invention relates to a pharmaceutical compo ⁇ sition comprising a humanized or chimeric monoclonal anti ⁇ body.
• the invention relates to the use of humanized or chimeric antibody for the manufacture of a medicament directed to tumors. Furthermore, the invention relates to the use of humanized or chimeric antibody for diagnostic locating and assessing tumor growth.
• the invention relates to a monoclonal antibody comprising a consensus sequence of variable regions of a heavy chain of a class or a subgroup of human immunoglobu- lins.
• pRVL425 HCM7-FV I b425-k
• the expression vector contains the sequences of the hypervariable regions (CDRs) of the murine antibody 425 and the FRs of the variable region and the constant (kappa) region of the light chain of the humanized anti ⁇ body. R is standing for "reshaped”.
• the expression vector contains the sequences of the hypervariable regions (CDRs) of the murine antibody 425 and the FRs of variable region and constant (gamma-1) region of the heavy chain of the humanized antibody. R is standing for "reshaped”.
• the expression vector contains the sequences of the FRs and hypervariable regions (CDRs) of the light 10 chain variable region of the murine antibody 425 and the constant (kappa) region of the light chain of human immunoglobulin. C is standing for chimeric.
• the expression vector contains the sequences of the FRs and hypervariable regions (CDRs) of the light chain variable region of the murine antibody 425 and the 0 constant region of the light chain of the human gamma-1 immunoglobulin. C is standing for chimeric.
• Hybridoma cell line 425 deposited on January 26, 1988, according to Budapest Treaty at the American Type Culture 5 Collection (ATCC) under the accession No. HB 9629.
• the cell line produces the murine antibody 425 which is directed to the EGF-receptor.
• microorganisms, cell lines, plasmids, promoters, resis ⁇ tance markers, replication origins or other fragments of vectors which are mentioned in the application are commer ⁇ cially or otherwise generally available. Provided that no other hints in the application are given, they are used only as examples and are not essential according to the invention and can be replaced by other suitable tools and biological materials, respectively.
• Bacterial hosts are preferably used for the amplification of the .corresponding DNA sequences. Examples for these host are: E. coli or Bacillus.
• Eukaryotic cells like COS (CVl origin SV40) or CHO (Chinese hamster ovary) cells or yeasts, for example, are preferred in order to produce the humanized and chimeric antibodies according to the invention.
• COS and CHO cells are preferred.
• Fig. 1 Schematic representations of the vectors used for the expression of chimeric and reshaped human antibodies. Restriction sites used in the construction of the expression plasmids are marked. The variable region coding sequences are represented by the dark boxes, constant regions by the light boxes, the HCMV pro ⁇ moter and enhancer by the hatched boxes, and the nucleotide fragment from the plasmid pSVneo by the speckled boxes. The directions of transcription are represented by arrows.
• Fig. 2 The nucleotide and amino acid sequences of the V H 425 (A), and V L 425 (B) cDNA as cloned into pUC18.
• the amino acids contributing to the leader are underlined and CDRs are indicated by brackets.
• the splice sites between the variable regions and constant regions are also shown.
• the front and back PCR-primers and their annealing sites, used in the construction of the genes coding for the chimeric antibodies, are shown.
• Fig. 3 The nucleotide and amino acid sequences of the syn ⁇ thesized gene fragment coding for reshaped human V H a425.
• the leader sequence is underlined and resi ⁇ dues contributing to the CDRs are bracketed.
• FIG. 4 Comparison of the amino acid sequences of mouse and reshaped human 425 variable regions.
• Panel A shows the sequences of mouse V L (V L 425) and reshaped human
• V L S (RV L a425 and RV L b425) .
• Panel B shows the sequences of mouse V H (V H 425) and reshaped human V H s (RV H a425, RV H b425, RV H c425, RV H d425, RV H e425, RV H f425, RV H g425, RV H h425, and RV H i425) .
• the FRs and CDRs are indicated. Amino acids are numbered according to Kabat et al., 1987.
• Fig. 5 Molecular model of the mouse MAb 425 variable regions.
• Fig. 6 Detection of binding to EGFR by ELISA. Antigen-bind ⁇ ing activity was assayed in dilutions of transfected COS cell supernatants and plotted as optical density at 450 nm against concentration of IgG (quantitated by ELISA, see Materials and Methods) .
• RV H a425 ⁇ , RV H b425 0, RV H C425 ⁇ , RV H d425 ®, RV H e425 D, RV H f425 B, RF H g425 D, RV H h425 O, RV H i425 o, RV H b425 co-trans- fected with RV L b425 is represented as ⁇ .
• a co-trans- fection of the chimeric VL425 and VH425 are repre ⁇ sented as •.
• FIG. 7 Competition for binding to antigen.
• Panel A shows competition between labelled mouse 425 antibody and
• Panel B shows competition between labelled mouse 425 antibody and (1) unlabelled mouse 425 anti ⁇ body (+) and (2) the reshaped human 425 antibodies produced by COS cells after co-transfection with HCMV-RV L a425-kappa and HCMV-RV H i425-gamma-l (o) , and with HCMV-RV L a425-kappa and HCMV-RV H g425-gamma-l (D ) .
• the horizontal axis represents the concentration of inhibitor (ng/ml) .
• the vertical axis represents percentage of inhibition of binding.
• FIG. 8 An examination of the effects of different reshaped human V L regions on antigen-binding.
• Panel A shows antigen-binding by reshaped human antibodies produced in COS cells transfected with HCMV-CV L 425-kappa and HCMV-CV H 425-gamma-l (•) , HCMV-RV L a 25-kappa and HCMV- RV H g425-gamma-l (Q) , HCMV-RV L b425-kappa and HCMV- RV H g425-gamma-l ( B ) , HCMV-RV L a425-kappa and HCMV-
• RV H c425-gamma-l ( ⁇ )
• HCMV-RV L b425-kappa and HCMV- RV H c425-gamma-l Panel B shows competition for binding to antigen between labelled mouse 425 anti ⁇ body and (1) unlabelled mouse 425 antibody (+) and ⁇ (2) reshaped human 425 antibodies produced in COS cells co-transfected with HCMV-V L a425-kappa and HCMV- V H g425-gamma-l (D) and with HCMV-V L b425-kappa and HCMV-V H g425-gamma-l ( a ) .
• the vertical axis represents the optical density at 450 nm ⁇ OD 45 o) and the horizontal axis represents the concentration of IgG (ng/ml) .
• the horizontal axis rep ⁇ resents the concentration of inhibitor (ng/ml) and the vertical axis represents percentage of inhibition of binding.
• Fig. 9 Panel A: Analysis of reshaped (lanes 1, 2), chimeric (lane 3) and murine (lane 4) MAbs 425 by SDS-PAGE under non-reducing conditions (a) and under reducing conditions (b) . Reshaped (lanes 7, 8) , chimeric (lane 9) and murine (lane 10) . Lanes 5, 6, 11, and 12 are
• Panel B Purification by gel filtration of reshaped MAb 425 on Superose 12. Peak 2 represents IgG.
• MAbs 425 to EGF-receptor (EGFR) MAbs 425 to EGF-receptor (EGFR) .
• the vertical axis represents the ratio bound (MAb) to total (MAb) in % (% bound/total) .
• the horizontal axis represents the concentration of antibody (mol/1 [log]) .
• V means MAb 425 murine o means MAb 425 chimeric •, T mean MAb 425 reshaped
• the vertical axis represents % bound/total (MAb) .
• the horizontal axis represents the concentration of anti ⁇ body (mol/1 [log] ) .
• A, V, D mean MAb 425 reshaped DETAILED DESCRIPTION
• Plasmid DNA is isolated from these colonies and analyzed by usual and commercially avail ⁇ able restriction enzyme digests to determine the size of the cDNA inserts. Clones that appear to have inserts 400-500 bp
• V L and V H cloning 15 or 500-600 bp for V L and V H cloning, respectively, are selected as candidates for sequencing.
• Three y clones and three V H clones are sequenced on both strands using Ml3 universal and reverse sequencing primers.
• Ml3 universal and reverse sequencing primers Of the three possi ⁇ ble V L clones sequenced, one codes for a complete variable
• V H clones Two of the V H clones code for identical V H regions while the other appears to code for the V H region with the intron ' between the leader sequence and FR-1 still present. Apart ?c - from the intron, the third V H clone contains coding sequence identical to that of the first two clones. To verify the sequence of the V L region, three more cDNA clones containing inserts of the appropriate size are sequenced. Two of these give sequences in agreement with the first V L clone. The third 0 is an unrelated DNA sequence. In the clones sequenced, not all of the original primer sequence are present. The extent of the deletions varies from clone to clone. These deletions, which probably occur during cDNA synthesis and cloning, may decrease the efficiency of the colony screening.
• the V L and V H genes for MAb 425 are shown in Figure 2.
• the amino acid sequence of the 425 V L and V H regions are compared to other mouse variable regions in the Kabat data base (Kabat et al., 1987) .
• the V L region can be classified into the mouse kappa chain variable region subgroup IV or VI.
• the 425 V L region has an approximately 86 % identity to the consensus sequence for mouse kappa subgroup IV and an approximately 89 % identity to subgroup VI.
• the 425 V L region appear to use the JK4 segment.
• Examination of the VH region shows an approximately 98 % identity to the FRs of the con ⁇ sensus sequence for mouse heavy chain subgroup II (B) .
• the right choice of a suitable class or subgroup of human immunoglobulin is dependent on the extent of the identity to the originally present chain in the non-human antibody.
• the identity of the deduced consensus sequence according to the present invention should be greater than ' 65 to 70 % compared with the sequence of the original non-human chain.
• the consensus sequences of the heavy chains are preferred especially, however, the consensus sequence of human heavy chain subgroup I. However, for other antibodies, the consen ⁇ sus sequences of other human heavy chains are suitable. The preferred consensus sequences are modified.
• the possible exchange of amino acids is 0 to 10 % according to the inven ⁇ tion, preferably 5 to 10 %. Construction and expression of chimeric 425 antibody:
• 3'ends these include introducing appropriate restriction enzyme sites so that the variable region coding sequences can be conveniently subcloned into the HCMV expression vectors. It is necessary to re-create donor splice sites in the 3'- flanking regions so that the variable regions are spliced correctly and efficiently to the constant regions.
• the 5'.- flanking regions are also modified to include a sequence that would create efficient initiation sites for translation by eukaryotic ribosomes (Kozak, 1987) . These modifications are introduced using PCR primers. The used primers are indicated in Table 1.
• two primers are preferably designed.
• 15 bases at the 3'-end of the primer are used to hybridize the primer to the template DNA while the 5'-end of the primer contains a Hindlll site and the "Kozak" sequence.
• the back primers have a similar design with 15 bases at the 3'-end used to hybridize the primer to the template DNA and the 5 , -end of the primer contains a BamHI site and a donor splice site.
• a Bglll site is used instead of BamHI site because the cDNA coding for the V L contains an internal BamHI site ( Figure 2) .
• the PCR reaction is preferably carried out as described in the examples.
• the PCR-modified V L region DNA is cloned into the Hindlll-
• Ba HI sites of the HCMV light chain expression vector as a Hindlll-Bglll fragment.
• This vector already contains the human genomic kappa constant region with the necessary splice acceptor site and poly(A + ) sites.
• the entire PCR-modified V L fragment is sequenced using two primers that anneal to sites flanking the cloning site in the expression vector. Sequenc ⁇ ing confirms that no errors have been incorporated during the PCR step.
• the PCR-modified V H DNA is cloned into the HCMV heavy chain expression vector as a Hindlll-BamHI fragment and also sequenced to confirm the absence of PCR errors.
• a BamHI fragment containing the human genomic gamma-1 constant region is inserted into the HCMV-CV H vector on the 3'-side of the V H region. This fragment contains the necessary acceptor splice site for the V-C splice to occur in vivo and the naturally occurring poly(A + ) site.
• the expression vectors containing the chimeric 425 V L and V H regions are co-transfected into appropriate eukaryotic cells, preferably COS cells. After approximately 72 h of transient expression, the cell culture medium is assayed by ELISA for human IgG production and for binding to EGFR protein. Amounts of human IgG detected in the media vary from 100-400 ng/ml. The chimeric antibody produced binds well to EGFR protein in a standard antigen-binding ELISA thus confirming that the correct mouse variable regions has been cloned and sequenced.
• a further comparison of the mouse 425 V H region with other mouse V H regions from the same Kabat subgroups is carried out to identity any FR residues which are characteristic of MAb 425 and may, therefore, be involved in antigen binding.
• the residue at position 94 of the mouse MAb 425 V H region is a serine while in other V H regions from mouse subgroup II (B) , and also from human subgroup I, residue 94 is an arginine (Kabat et al., 1987) .
• This amino acid substitution is an unusual one and, since position 94 is adjacent to CDR-3, it is at a surprisingly important position.
• the reshaped human 425 V H region is preferably designed based on the CDRs of mouse MAb 425 and FRs derived from the consen- sus sequence for human subgroup I FRs (as defined by Kabat et al., 1987) . Positions 94 in FR-3 is made a serine as found in mouse MAb 425. At positions in the consensus sequence for human subgroup I FRs where no single amino acid are listed, the most commonly occurring amino acid at that position is selected. If there is no preferred amino acid at a particular position in the human consensus sequence, the amino acid that is found at that position in the sequence of mouse MAb 425 V H is selected.
• the resulting amino acid sequence comprises the first version (versions "a") of reshaped human 425 V H ( Figure 3) . All subsequent versions of reshaped human 425 V H are modifications of this first version.
• a 454 bp DNA fragment coding for the reshaped human 425 V H region, as described above, is designed and synthesized (see examples and Figure 3) .
• this DNA fragment also contains sequences coding for a human leader sequence.
• the human leader sequence can be taken for example from antibody HG3 CL (Rechavi et al., 1983), a member of human V H subgroup I (Kabat et al., 1987) .
• the synthetic DNA fragment also contains eukaryontic translation signals at the 5' ' -end (Kozak, 1987), a donor splice site at the 3'-end (Breathnach et al., 1978), and HindiII and BamHI sites at the 5'- and 3'-ends, respectively, for subcloning into the HCMV expression vector.
• oligonu- cleotides are designed that contain internal DNA sequences coding for the three CDRs of mouse 425 V L region and also contain 12 bases at the 5'- and 3'-ends designed to hybridize to the DNA sequences coding for the human FRs in reshaped human D1.3 V L region (see oligonucleotides 7-9 in Table I) .
• CDR-grafting is carried as described in the examples. After DNA sequencing of putative positive clones from the screen ⁇ ing, the overall yield of the triple mutant is 5-15 %, pref ⁇ erably 9-10 %.
• PCR errors is cloned as a Hindlll-BamHI fragment into the light chain expression vector to create the plasmid HCMV- RV L a425-kappa ( Figure 1) .
• a molecular model of the mouse 425 variable regions is made ( Figure 5) .
• the model is based on the structure of HyHEL-5, a structurally-solved antibody whose variable regions exhibit a high degree of homology to those of mouse 425 antibody.
• amino acid residues at positions 30, 48, 67, 68 and 71 in the reshaped human 425 V H region are changed to be identi ⁇ cal to the amino acids occurring at those positions in mouse 425 V H region.
• a variety of combinations of these changes are constructed and tested according to the invention.
• the nine versions of reshaped human V H region can be grouped according to their ability to bind to EGFR.
• Reshaped human V H region version "g” and “i” provide the highest levels of binding, followed by version “c", “f”, and “h”, and then followed by version "b".
• version "e” gives low, but detectable, levels of binding.
• Versions "a” and “d” never give detectable levels of binding.
• a competition binding assay is used to directly compare the reshaped human 425 antibodies containing versions "g” and "i” of V H , and the chimeric 425 antibody, to mouse 425 antibody ( Figure 7) .
• the expression vector containing the RV L b425 was co-trans- fected into appropriate preferably eukaryotic cells with the expression vector containing reshaped human V H region versions
• the reshaped human MAb 425 with V L b and V H g has an avidity for antigen 60-80 % of that of the murine MAb 425. From other experiments, using a reshaped human antibody containing V L b plus V H g (Examples 10, 11) it can be seen, that the binding potency to EGFR is similar for chimeric, reshaped and murine antibodies. 5
• the invention demonstrates that relatively conservative changes in the FR residues can strongly influence antigen- binding.
• H2 of mouse 425 antibody is a member of H2, group 2 canonical structures as defined by Chothia et al., 0 1989.
• HyHEL-5 has an H2 with an amino acid sequence similar to that of the H2 of mouse 425 antibody.
• a Pro at position 52A in CDR-2 packs into a cavity created by the small amino acid (Ala) at position 71 in the FRs.
• Al small amino acid
• Lys-66 forms a salt bridge with Asp-86.
• Introduction of larger Arg residue at position 66 would disrupt the structure.
• Ala-67 may interact with CDR-2 and simultaneously changing residues 66 and 67 to Arg and Val, as in V H a425, could have an adverse steric effect on CDR-2.
• the residue at position 48 is known to be buried (Chothia and Lesk, 1987), and the model confirms this. Changing residue 48 from an lie, as found in mouse 425 antibody, to a Val, as found in human V H regions of subgroup I, could affect antigen binding by generally disrupting the structure.
• the amino acid at position 48 is also close to CDR-2 and may have a subtle steric effect on the CDR-2 loop.
• V H g has all 5 of the FR changes discussed above plus the change at position 94 that is included in the first version of reshaped human 425 V H region.
• the FRs in version "b" of reshaped human 425 V L region are 70 % identical to those in mouse 425 V L region.
• the FRs in version "g” of reshaped human 425 V H region are 80 % identical to those in mouse.
• the antibodies according to the invention can be administered to human patients for therapy or diagnosis according to known procedures.
• the antibody, or antibody fragments will be injected parenterally, preferably intraperitoneally.
• the monoclonal antibodies of the invention can also be administered intravenously.
• the dosage ranges for the administration of the monoclonal antibodies of the invention are those large enough to produce the desired tumor suppressing effect.
• the dosage should not be so large as to cause adverse side effects, such as unwanted cross reactions, anaphylactic reactions, and the like.
• the dosage will vary with the age, condition, sex and extent of the disease in the patient and can be determined by one of skill in the art.
• the dosage can be adjusted by the individ ⁇ ual physician in the event of any counter indications, immune tolerance or similar conditions. Dosage can vary from 0.1 mg/kg to 70 mg/kg, preferably 0.1 mg/kg to 500 mg/kg/dose, in one or more doses administrations daily, for one or several days.
• Preparations for parenteral administration includes sterile aqueous or non-aqueous solutions, suspensions, and emulsions.
• non-aqueous solvents are propylene glycol, poly- ethylene glycol, vegetable oils such as olive oil, and injectable organic esters such as ethyl oleate.
• Aqueous carriers include water, alcoholic/aqueous solutions, emul ⁇ sions or suspensions, including saline and buffered media.
• Parenteral vehicles include sodium chloride solution, Ring- er's dextrose, dextrose and sodium chloride, lactated Ring ⁇ er's or fixed oils.
• Intravenous vehicles include fluid and nutrient replenishers, electrolyte replenishers, such as those based on Ringer's dextrose, and the like. Preservatives and other additives may also be present such as for example, antimicrobials, antioxidants, chelating agents, and inert gases and the like.
• the antibodies can be conjugated to a toxin such as ricin subunit A, diptheria toxin, or toxic enzyme. Alternatively it can be radiolabelled according to known methods in the art.
• the antibody of the present invention display excel ⁇ lent cytotoxicity, in the absence of toxin, in the presence of effector cells, i.e. human monocytes.
• effector cells i.e. human monocytes.
• Solid tumors which can be detected and treated using the present methods include melanoma, glioma and carcinoma.
• Cancer cells which do not highly express EGFR-receptors can be induced to do so using lymphokine preparations. Also lymphokine preparations may cause a more homogenous expres ⁇ sion of EGF-receptors among cells of a tumor, leading to more effective therapy.
• Lymphokine preparations suitable for administration include interferon-gamma, tumor necrosis factor, and combinations thereof. These can be administered intravenously. Suitable dosages of lymphokine are 10,000 to 1,000,000 units/patient.
• the antibody can be conjugated to a radio-opaque dye or can be radiolabelled.
• a preferred label ⁇ ling method is the Iodogen method (Fraker et al., 1978) .
• the antibody will be administered as F(ab') 2 fragments for diagnostic purposes. This provides superior results so that background substraction is unnecessary.
• Fragments can be prepared by known methods (e.g., Herlyn et al., 1983) . Generally pepsin digestion is performed at acid pH and the fragments are separated from undigested IgG and heavy chain fragments by Protein A-SepharoseTM chromatography.
• the reshaped human 425 antibodies according to the invention are less likely than either mouse or chimeric 425 antibodies to raise an immune response in humans.
• the avidity of the best version of reshaped human 425 antibody equals that of mouse or chimeric 425 antibody in the best embodiments of the invention. Binding studies show that the potency to compete with EGF for binding to EGFR under optimized conditions is the same for chimeric, reshaped and murine antibodies.
• the reshaped human 425 antibodies are more efficacious, when used therapeutically in humans, than either the mouse or chimeric 425 antibodies. Due to the great reduction in immunogenicity, the reshaped human 425 antibody has a longer half-life in humans and is the least likely to raise any adverse immune response in the human patient.
• Double-stranded cDNA was synthesized essentially according to the methods of Gubler and Hoffman (1983) except that primers homologous to the 5'-regions of the mouse kappa and gamma-2a immunoglobulin constant regions were used to prime first-strand synthesis
• the design of the light chain primer was a 26-mer (oligonucleotide 1, Table I) which was designed based on published data (Levy et al., 1987; Kaariten et al., 1983) .
• the design of the heavy chain primer was a 25-mer (oligonucleotide 2, Table I) and designed based on published data (Kaariten et al., 1983; Kabat et al., 1987) .
• Primers were designed and synthesized on an Applied Biosystems 380B DNA Synthesizer and purified on urea-acrylamide gels.
• the blunt-ended cDNAs were cloned into Smal-digested pUC18 (commercially available) and trans ⁇ formed into competent E. coli cells, e.g. DH5-alpha (commer ⁇ cially available) . Colonies were gridded onto agar plates and screened by hybridization using 32 P-labelled first-strand synthesis primers (Carter et al., 1985) . Sequencing of dou- ble-stranded plasmid DNA was carried out using Sequenase (United States Biochemical Corporation) .
• Example 2 Example 2
• PCR polymerase chain reaction
• PCR reactions were phenol/chloroform extracted twice and ethanol precipitated before digesting with Hindlll and BamHI.
• the PCR fragment coding for the V L or V H region was then cloned into an expression vector.
• This vector contains the HCMV (human cytomelovirus) enhancer and promoter, the bacterial neo gene, and the SV40 origin of replication.
• a 2.0 Kb BamHI fragment of genomic DNA coding for the human gamma-1 constant region (Takahashi et al., 1982) was inserted in the correct orientation downstream of the V H region frag- ment (see HCMV-CV H 425-gamma-l in Figure 1) .
• This vector was later adapted by removing the BamHI site at the 3'-end of the constant region fragment thus allowing variable regions to be directly inserted into the heavy chain expression vector as
• Hindlll-BamHI fragments (Maeda et al., 1991) .
• the fragment . . . coding for the V L region was inserted into a similar HCMV expression vector in this case containing a BamHI fragment of genomic DNA, approximately 2.6 Kb in size, coding for the human kappa constant region and containing a splice acceptor site and a poly(A + ) (Rabbitts et al., 1984) (see HCMV-CV L -425- kappa in Figure 1) .
• variable regions of murine MAb 425 were built on the solved structure of the highly homologous anti-lysozyme antibody, HyHEL-5 (Sheriff et al., 1987) .
• the variable regions of MAb 425 and HyHEL-5 have about 90 % - • -* homology.
• the model was built on a Silicon Graphics Iris 4D workstation running UNIX and using the molecular modeling package "QUANTA" (Polygen Corp.) . Identical residues in the framework 0 were retained; non-identical residues were substituted using the maximum overlap (Snow and Amzel, 1986) incorporated into QUANTA'S protein modeling facility.
• the main chain conforma ⁇ tion of the three N-terminal residues in the heavy chain were substituted from a homologous antibody structure (HyHEL-10 5 (Padlan et al., 1989)) since their temperature factors were abnormally high (greater than the mean plus three standard deviations from the backbone temperature factors) and since they influence the packing of V H CDR-3 (H3) (Martin, 1990) .
• MAb 425 corresponded to canonical forms postulated by Chothia et al. (1989) .
• the main chain torsion angles of these loops were kept as in HyHEL-5.
• the CDR-3 (L3) sequence of the V L region and the CDR-3 (H3) of the V H region from MAb 425 did not correspond to canonical structures and, therefore, were modeled in a different way.
• the computer program of Martin et al. (1989) was used to extract loops from the Brookhaven Databank (Bernstein et al., 1977) . The loops were then sorted based on sequence similarity, energy, and structure-determin ⁇ ing residues (Sutcliffe, 1988) .
• H3 was modeled on bovine glutathione peroxidase (Epp et al., 1983) in the region of residues 92-103.
• L3 was modelled on the murine IgA (J539) Fab fragment (Suh et al., 1986) in the region of residues 88-96 of the light chain.
• the model was subjected to steepest descents and conjugate gradients energy minimization using the CHAR potential (Brooks et al., 1983) as implemented in QUANTA in order to relieve unfavorable atomic contacts and to optimize Van der Waals and electrostatic interactions.
• 425 light chain was carried out using a CDR-grafting approach similar to that described by Reichmann et al. (1988) and Verhoeyen et al. (1988) .
• Single-stranded template DNA was prepared from a M13m.pl8 vector (commercially available) containing a Hindlll-BamHI fragment coding for the human anti-lysozyme V L region (EP 239 400, G. Winter) .
• the FRs of this light chain are derived from the crystallographically- solved protein REI.
• oligonucleotides were designed which consisted of DNA sequences coding for each of the mouse MAb 425 light chain CDRs flanked on each end by 12 bases of DNA complementary to the DNA sequences coding for the adja ⁇ cent FRs of human REI (oligonucleotides 7-9 in Table I) . Oligonucleotides were synthesized and purified as before.
• oligonucleotides were phosphorylated and used simulta- neously in an oligonucleotide-directed in vitro mutagenesis system based on the methods of Eckstein and coworkers (Taylor et al., 1985; Nakamaye and Eckstein, 1986; and Sayers et al., 1988) .
• the manufacturer's instructions were followed through the exonuclease III digestion step.
• the reaction was then phenol/chloroform extracted, ethanol precipitated, and resus- pended in 100 ⁇ l of TE.
• a volume of 10 ⁇ l was used as tem ⁇ plate DNA in a 100 ⁇ l PCR amplification reaction containing Ml3 universal primer and reverse sequencing primer to a final concentration of 0.2 ⁇ M each. Buffer and thermocycling condi- tions were as described in Example 2 with the exception of using a 55 °C annealing temperature.
• the PCR reaction was phenol/chloroform extracted twice and ethanol precipitated before digestion with Hindlll and BamHI and subcloning into pUCl ⁇ . Putative positive clones were identified by hybridiza ⁇ tion to 32 P-labelled mutagenic primers (Carter et al., 1987) . Clones were confirmed as positive by sequencing.
• a V L region containing all three grafted CDRs was cloned as a HindiII- BamHI fragment into the V L expression vector to create the plasmid HCMV-RV L a425-kappa.
• Version "b” of the reshaped V L was constructed using the PCR mutagenesis method of Kammann et al. (1989), with minor modifications.
• the template DNA was the RVa subcloned into pUCl ⁇ .
• the first PCR reaction was set up in a total volume of 50 ⁇ l and contained 1 ng template.
• Ml3 reverse sequencing primer and primer 10 (Table I) at a final concentrations of 1 ⁇ M, 200 ⁇ M dNTPs, 10 mM Tris-HCl (pH 8.3), 50 mM KC1, 1.5 mM MgCl, and 0.01 % (w/v) gelatin.
• Amplitaq DNA polymerase was added at a concentration of 1 unit per assay. The reaction was set up in triplicate.
• the reactions were cycled at 1 min 94 °C, 1 min 37 °C, and 2 min 72 °C for 40 cycles, followed by an extension at 72 °C for 10 min.
• the reactions were pooled, phenol/chloroform extracted and ethanol precipitated before isolating the PCR product from a TAE agarose gel.
• a tenth of the first PCR reaction was then used as one of the primers in the second PCR reaction.
• the second reaction was as the first except the first reaction product and 20 pmol of M13 universal primer were used. Cycling was as described by Kammann et al. (1989) .
• the Hindlll-BamHI fragment was cloned into pUC18 and sequenced.
• a DNA fragment bearing the desired change was subcloned into the V L expression plasmid to create plasmid HCMV-RV L b 25-kappa.
• the first version of the reshaped human V H region of 425 was chemically synthesized.
• a DNA sequence was designed coding for the required amino acid sequence and containing the necessary flanking DNA sequences (see above) . Codon usage was optimized for mammalian cells with useful restriction enzyme sites engineered into the DNA sequences coding for FRs.
• the 454 bp was synthesized and subcloned into pUCl ⁇ as an EcoRI- Hindlll fragment.
• a Hindlll-BamHI fragment coding for the reshaped humanized 425 heavy chain was then transferred into the V H expression vector, to produce the plasmid HCMV-
• RV H a-425-gamma-l RV H a-425-gamma-l.
• f and g in pUCl ⁇ . These versions were subcloned into the heavy chain expression vector as Hindlll-BamHI fragments to create plasmids HCMV-RV H d425-gamma-l, HCMV-RV H e425-gamma-l, HCMV-RV H f425-gamma-l, and HCMV-RV H g425-gamma-l.
• Reshaped human 425 V H regions versions "b” and “c” were generated using the PCR mutagenesis method of Kammann et al. (1989) as described above.
• the template DNA was reshaped human 425 V H region version "a” subcloned into pUCl ⁇ , and the utagenic primer used in the first PCR reaction was either primer 13 or 14 (Table I) .
• sequences bearing the desired changes were subcloned into the heavy chain expression plasmid to create plasmids.
• Reshaped heavy chain versions "h” and “i” were constructed from the pUC-based clones of existing versions.
• a 0.2 Kb Hindlll-Xhol fragment from version "e” was ligated to a 2.6 Kb Xhol-Hindlll fragment from either version "b” or "c” producing the new versions "h” and "i", respectively.
• Hindlll-BamHI fragments coding for these versions were sub ⁇ cloned into the heavy chain expression vector to produce the HCMV-RV H h425-gamma-l and HCMV-RV H i425-gamma-l.
• COS cells were electroporated with 10 ⁇ g each of the expres ⁇ sion vectors bearing the genes coding for the heavy and light chains. Briefly, 10 ⁇ g of each plasmid was added to a 0.8 ml aliquot of a 1 x 10 7 cells/ml suspension of COS cells in PBS. A Bio-RadTM Gene Pulser was used to deliver a pulse of 1900 V, with a capacitance of 25 ⁇ F. The cells were left to recover at room temperature for 10 min before plating into 8 ml DMEM containing 10 % fetal calf serum. After 72 h incubation, the media was collected, centrifuged to remove cellular debris, and stored under sterile conditions at 4 °C for short periods, or at -20 °C for longer periods, prior to analysis by ELISA.
• Human IgG present in COS cell supernatants was detected by ELISA: In the ELISA assay for human IgG, 96-well plates were coated with goat anti-human IgG (whole molecule) and human IgG in the samples that bound to the plates was detected using alkaline phosphatase-conjugated goat anti-human IgG (gamma-chain specific) . Purchasable purified human IgG was used as a standard. Binding to the antigen recognized by MAb 425 was determined in a second ELISA.
• EGFR protein preparation obtainable, for example, accord- ing to Rodeck et al., 1980
• antibodies binding to EGFR were detected using either an anti-human IgG (gamma-chain specific) peroxidase conjugate (for chimeric and reshaped human antibodies) or an anti-mouse IgG (whole molecule) peroxidase conjugate (for the mouse MAb 425 antibody) (both conjugates supplied by Sigma) .
• Purified murine MAb 425 was used as a standard.
• Murine MAb 425 was biotinylated using a correspondingly purchasable kit. ELISA plates were coated with an optimal dilution of the EGFR protein. Dilutions of the COS cell supernatants, in a volume of 50 ⁇ l, were mixed with 50 ⁇ l of the biotinylated murine MAb 425 (estimated by ELISA to be 1.75 ⁇ g/ml) . Each COS cell supernatant was tested in dupli ⁇ cate. Plates were incubated at room temperature, overnight. Bound biotinylated murine MAb 425 was detected by the addi ⁇ tion of a purchasable streptavidin horseradish peroxidase complex. A control with no competitor present allowed a value of percentage of inhibition or blocking to be calculated for each COS cell supernatant as follows:
• Reshaped MAb 425 was purified by gelspacefiltration on Super- ose 12TM (Pharmacia Corp. Sweden) according to standard meth- ods. The antibody was eluted with PBS (pH 7.4, 0.8 M NaCl) (0.1 M) . A single peak (at 5 min) can be obtained (Fig. 9 (B)).
• Biotin-labelled MAb 425 was used to compete with unlabelled MAb 425 or derivates for binding to EGFR. Biotin-labelling occurred according to standard methods. EGFR was solubilized from A431 membranes by standard methods. A431 cells were commercially purchased. Detection was done after incubation with POD-conjugated streptavidin and substrate. From this data inhibition curves were constructed (Fig. 10) . The curves show that the binding of the various antibodies are compara ⁇ ble.

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Life Sciences & Earth Sciences (AREA)
• Medicinal Chemistry (AREA)
• General Health & Medical Sciences (AREA)
• Biophysics (AREA)
• Biochemistry (AREA)
• Genetics & Genomics (AREA)
• Immunology (AREA)
• Molecular Biology (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Animal Behavior & Ethology (AREA)
• Veterinary Medicine (AREA)
• General Chemical & Material Sciences (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Pharmacology & Pharmacy (AREA)
• Virology (AREA)
• Public Health (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Gastroenterology & Hepatology (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Peptides Or Proteins (AREA)
• Preparation Of Compounds By Using Micro-Organisms (AREA)
• Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
• Micro-Organisms Or Cultivation Processes Thereof (AREA)

Priority Applications (13)

Applications Claiming Priority (2)

Publications (1)

Family

ID=8206486

Family Applications (1)

Country Status (19)

Cited By (51)

Families Citing this family (294)

Family Cites Families (3)

• 1992
  • 1992-03-04 AU AU13403/92A patent/AU658396B2/en not_active Expired
  • 1992-03-04 DK DK92905860T patent/DK0531472T3/da active
  • 1992-03-04 KR KR1019920702755A patent/KR100240308B1/ko not_active Expired - Lifetime
  • 1992-03-04 ES ES92905860T patent/ES2204890T3/es not_active Expired - Lifetime
  • 1992-03-04 DE DE69233153T patent/DE69233153T2/de not_active Expired - Lifetime
  • 1992-03-04 EP EP92905860A patent/EP0531472B1/en not_active Expired - Lifetime
  • 1992-03-04 HU HU9203484A patent/HU219537B/hu unknown
  • 1992-03-04 SK SK3327-92A patent/SK281142B6/sk not_active IP Right Cessation
  • 1992-03-04 WO PCT/EP1992/000480 patent/WO1992015683A1/en not_active Ceased
  • 1992-03-04 EP EP03018303A patent/EP1362868A3/en not_active Ceased
  • 1992-03-04 CA CA002082160A patent/CA2082160C/en not_active Expired - Lifetime
  • 1992-03-04 JP JP50595192A patent/JP3854306B2/ja not_active Expired - Lifetime
  • 1992-03-04 US US07/946,421 patent/US5558864A/en not_active Expired - Lifetime
  • 1992-03-04 SK SK360-99A patent/SK281143B6/sk not_active IP Right Cessation
  • 1992-03-04 CZ CZ963337A patent/CZ283717B6/cs not_active IP Right Cessation
  • 1992-03-04 AT AT92905860T patent/ATE247168T1/de active
  • 1992-03-04 CZ CS923327A patent/CZ282603B6/cs not_active IP Right Cessation
  • 1992-03-05 IE IE070592A patent/IE920705A1/en not_active IP Right Cessation
  • 1992-03-05 ZA ZA921661A patent/ZA921661B/xx unknown
  • 1992-03-05 PT PT100195A patent/PT100195B/pt not_active IP Right Cessation
  • 1992-03-06 MX MX9201016A patent/MX9201016A/es unknown
  • 1992-03-09 TW TW081101780A patent/TW222279B/zh not_active IP Right Cessation

Non-Patent Citations (8)

Also Published As

Similar Documents

Legal Events